^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-8543

    i
    Other names: JNJ-8543, JNJ-80948543, JNJ80948543, JNJ8543, JNJ 80948543, JNJ 8543
    Associations
    News

    Trials

    Company:
    J&J
    Drug class:
    CD20 inhibitor, CD3 agonist, T-cell stimulant, CD79B inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT05424822)
    Phase 1
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    08/18/2022
    Primary completion :
    07/31/2024
    Completion :
    10/30/2026
    BCL2
    |
    JNJ-8543